Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

	Sep '13	Sep '14	Sep '15	Sep '16	Sep '17	Sep '18	Sep '19	Sep '20	Sep '21	Sep '22
asset turnover	1.07 -	1.07 0.03%	1.06 0.40%	0.78 26.75%	0.80 3.23%	0.85 5.70%	0.62 27.31%	0.63 1.35%	0.71 12.93%	0.72 1.73%
cash conversion cycle	208.45 -	200.56 3.78%	195.14 2.70%	250.49 28.36%	215.25 14.07%	212.19 1.42%	207.58 2.17%	240.11 15.67%	265.16 10.43%	178.07 32.85%
cash per share	1.07 -	1.04 3.33%	1.20 15.52%	1.12 6.29%	1.35 20.34%	1.41 4.38%	1.47 3.80%	1.25 14.80%	1.15 7.86%	1.88 63.66%
company equity multiplier	1.14 -	1.10 3.62%	1.10 0.57%	1.51 36.90%	1.47 2.63%	1.43 2.71%	1.70 18.94%	1.64 3.98%	1.37 16.30%	1.26 8.15%
days of inventory outstanding	187.97 -	180.97 3.72%	179.21 0.97%	240.81 34.37%	199.44 17.18%	184.42 7.53%	174.87 5.18%	229.54 31.26%	240.24 4.66%	171.10 28.78%
days of payables outstanding	30.17 -	25.32 16.09%	33.25 31.34%	40.76 22.58%	37.10 8.98%	27.49 25.90%	31.95 16.21%	44.84 40.36%	36.58 18.42%	44.81 22.49%
days of sales outstanding	50.65 -	44.91 11.34%	49.18 9.53%	50.45 2.57%	52.91 4.89%	55.26 4.44%	64.66 17.00%	55.41 14.29%	61.51 10.99%	51.77 15.83%
dividend yield	0.03 -	0.04 38.81%	0.05 4.81%	0.04 11.32%	0.04 3.13%	0.03 15.87%	0.03 22.38%
ebit per revenue	0.30 -	0.28 8.66%	0.29 3.71%	0.26 8.94%	0.19 28.94%	0.15 20.57%	0.16 10.00%	0.24 48.61%	0.29 21.06%	0.16 44.19%
ebt per ebit	1.00 -	0.99 0.63%	0.98 1.24%	0.99 0.36%	0.97 1.14%	0.96 1.30%	0.97 0.33%	0.97 0.19%	0.97 0.55%	1.00 2.72%
effective tax rate	0.34 -	0.33 1.11%	0.35 6.39%	0.36 2.56%	0.41 12.27%	0.21 47.34%	0.23 5.76%	0.22 2.78%	0.21 4.75%	0.22 3.69%
enterprise value multiple	14.76 -	11.97 18.93%	10.99 8.20%	14.12 28.53%	13.01 7.89%	15.47 18.90%	9.60 37.91%	9.87 2.73%	7.88 20.08%	18.24 131.33%
fixed asset turnover	7.23 -	6.84 5.43%	7.09 3.62%	6.44 9.13%	6.58 2.19%	7.12 8.20%	6.58 7.64%	6.77 2.98%	6.49 4.20%	6.57 1.23%
free cash flow per share	1.00 -	0.75 24.47%	0.91 21.11%	0.79 13.41%	0.87 10.58%	0.72 17.36%	0.75 4.14%	1.04 38.54%	1.12 7.66%	1.70 51.89%
gross profit margin	0.64 -	0.62 3.22%	0.63 0.76%	0.65 4.18%	0.62 4.59%	0.61 1.76%	0.59 3.64%	0.62 4.64%	0.63 2.73%	0.57 10.61%
interest coverage				57.28 -	22.77 60.25%	20.78 8.73%	16.81 19.09%	23.30 38.59%	49.54 112.62%	45.75 7.66%
inventory turnover	1.94 -	2.02 3.87%	2.04 0.98%	1.52 25.58%	1.83 20.74%	1.98 8.14%	2.09 5.46%	1.59 23.81%	1.52 4.45%	2.13 40.41%
long term debt to capitalization				0.25 -	0.23 7.61%	0.20 10.65%	0.28 39.38%	0.22 23.48%	0.16 25.06%	0.07 55.01%
net income per ebt	0.66 -	0.67 0.56%	0.65 3.20%	0.64 1.40%	0.59 7.01%	0.79 32.66%	0.77 1.58%	0.78 0.82%	0.79 1.35%	0.78 0.98%
net profit margin	0.20 -	0.18 8.72%	0.18 0.86%	0.16 9.90%	0.11 34.68%	0.11 4.00%	0.12 8.62%	0.18 50.11%	0.22 23.37%	0.13 43.24%
operating cash flow per share	1.08 -	0.92 14.37%	1.03 11.34%	0.89 13.78%	0.98 10.63%	0.82 16.16%	0.84 2.42%	1.12 33.01%	1.55 38.07%	1.90 23.18%
operating cycle	238.62 -	225.88 5.34%	228.40 1.12%	291.25 27.52%	252.35 13.36%	239.69 5.02%	239.53 0.06%	284.95 18.96%	301.74 5.89%	222.87 26.14%
operating profit margin	0.30 -	0.28 8.66%	0.29 3.71%	0.26 8.94%	0.19 28.94%	0.15 20.57%	0.16 10.00%	0.24 48.61%	0.29 21.06%	0.16 44.19%
payables turnover	12.10 -	14.42 19.18%	10.98 23.86%	8.95 18.42%	9.84 9.87%	13.28 34.95%	11.42 13.95%	8.14 28.75%	9.98 22.59%	8.15 18.36%
pretax profit margin	0.30 -	0.28 9.23%	0.28 2.42%	0.26 8.61%	0.18 29.75%	0.14 21.60%	0.16 10.36%	0.23 48.89%	0.28 21.73%	0.16 42.68%
price fair value	6.28 -	4.55 27.52%	4.29 5.70%	4.87 13.35%	3.56 26.92%	3.57 0.24%	2.12 40.68%	2.94 38.90%	2.54 13.73%	3.71 46.17%
receivables turnover	7.21 -	8.13 12.79%	7.42 8.70%	7.23 2.51%	6.90 4.66%	6.60 4.25%	5.65 14.53%	6.59 16.68%	5.93 9.90%	7.05 18.80%
return on assets	0.22 -	0.20 8.74%	0.19 1.25%	0.13 34.00%	0.09 32.57%	0.09 9.93%	0.07 21.04%	0.11 52.13%	0.16 39.32%	0.09 42.26%
return on capital employed	0.37 -	0.32 13.15%	0.33 3.92%	0.22 32.83%	0.16 26.48%	0.14 15.63%	0.11 22.77%	0.17 61.93%	0.23 32.93%	0.13 41.91%
return on equity	0.25 -	0.22 12.04%	0.21 0.69%	0.19 9.64%	0.13 34.34%	0.14 6.95%	0.13 6.09%	0.19 46.08%	0.22 16.62%	0.12 46.96%
total debt to capitalization				0.26 -	0.24 6.11%	0.22 8.73%	0.28 27.77%	0.22 21.93%	0.17 24.64%	0.08 53.60%

NASDAQ:VIVO

Meridian Bioscience, Inc.

Last Close

33.97

30/01 21:00

Market Cap

1.49B

Beta: -

Volume Today

5.63M

Avg: 686.61K

PE Ratio

−551.87

PFCF: 42.66